Text Size

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00036127
First received: May 7, 2002
Last updated: April 7, 2011
Last verified: September 2007
History of Changes
  Purpose

Study to learn if the alternate formulation is effective in agitated schizophrenic patients


Condition Intervention Phase
Schizophrenia
 Drug: aripiprazole
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Study Start Date: April 2002
Study Completion Date: January 2003
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Agitated schizophrenic patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036127

Locations
United States, California
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Chula Vista, California, United States
Local Institution
Rosemead, California, United States
Local Institution
San Diego, California, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Macon, Georgia, United States
United States, Illinois
Local Instituton
Hoffman Estates, Illinois, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Hampshire
Local Institution
Nashua, New Hampshire, United States
United States, New York
Local Institution
New York, New York, United States
United States, Ohio
Local Institution
Beachwood, Ohio, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, South Carolina
Local Institution
Charleston, South Carolina, United States
United States, Texas
Local Institution
Houston, Texas, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site

No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00036127     History of Changes
Other Study ID Numbers: CN138-050
Study First Received: May 7, 2002
Last Updated: April 7, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
agitated schizophrenic patients

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
 Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 19, 2013